NCI Initiates Preclinical Investigation of Ivermectin as Potential Anticancer Agent (February 2026)
In February 2026, the National Cancer Institute announced it had begun preclinical laboratory studies to evaluate ivermectin's potential anticancer properties. This is a significant signal from the world's largest cancer research institution.
By Sanare Lab · May 21, 2026 · 5 min read
When the National Cancer Institute decides to study a compound, the oncology world pays attention. In February 2026, reporting revealed that the NCI had opened preclinical laboratory work on ivermectin — a drug better known for treating parasites than tumors. For patients and advocates who have followed the repurposed-drug story for years, this felt like validation. The reality is more nuanced, and understanding what a preclinical NCI investigation does and does not tell us is essential to interpreting the news responsibly.
Table of Contents
The NCI Announcement: What It Means
In February 2026, reporting by STAT News and Oncology Nursing News revealed that the National Cancer Institute (NCI) — the U.S. federal government's principal agency for cancer research and part of the National Institutes of Health — had begun preclinical laboratory studies to evaluate ivermectin as a potential anticancer agent. For a compound that has largely been studied outside mainstream oncology, an NCI investigation is a notable development.
The significance is as much structural as scientific. Ivermectin is off-patent, which means no pharmaceutical company can recoup the tens of millions of dollars a full development program costs by selling an exclusive product afterward. This "market failure" is exactly the kind of gap that public institutions like the NCI exist to fill. By taking ivermectin into its own laboratories, the NCI is signaling that the accumulated preclinical literature is credible enough to warrant systematic, well-controlled evaluation — even though there is no commercial sponsor.
It is equally important to state what the announcement does not mean. It is not an endorsement, a change in the standard of care, or evidence that ivermectin works in cancer patients. It is the beginning of a disciplined scientific process whose outcome is genuinely uncertain.
What Is Preclinical Research — and Why It Matters
Drug development proceeds in stages, and preclinical research is the earliest laboratory phase — the work done before a compound is ever given to patients in a formal trial. It typically involves two kinds of experiments: in vitro studies using cancer cell cultures in a dish, and in vivo studies in animal models such as mice bearing human tumor xenografts. These experiments probe whether a drug kills or slows cancer cells, at what concentrations, through what mechanisms, and with what apparent toxicity.
Preclinical evidence is necessary but far from sufficient. The sobering reality of oncology drug development is that the vast majority of compounds that show activity in the lab fail in human trials — often because the concentrations that work in a dish cannot be safely achieved in the human bloodstream, or because tumors in living people are far more complex and adaptable than cell lines. This is why the NCI's step, while encouraging to advocates, must be understood as an early checkpoint rather than a destination. Positive preclinical results would justify moving toward carefully designed human trials; they would not, on their own, justify patient use.
Proposed Mechanisms: How Ivermectin May Target Cancer
The preclinical case for ivermectin rests on a surprisingly broad set of proposed mechanisms, which is part of what makes it scientifically interesting. Published laboratory work has described several overlapping effects:
- Wnt/β-catenin inhibition — this pathway is frequently hyperactive in cancers and drives proliferation and stemness; ivermectin appears to suppress it in models.
- PI3K/Akt/mTOR suppression — a central growth-and-survival signaling axis whose inhibition can slow tumor cell proliferation.
- STAT3 inhibition — STAT3 supports tumor survival, inflammation, and immune evasion.
- Apoptosis induction — promoting programmed cell death in cancer cells.
- Cancer stem cell targeting — potentially reaching the treatment-resistant cell subpopulation implicated in relapse.
- Mitochondrial effects — disrupting cancer-cell energy metabolism.
- Angiogenesis inhibition — impairing the tumor's ability to grow new blood vessels.
This multi-pathway profile is a double-edged sword. On one hand, hitting several targets could make resistance harder to develop. On the other, a drug that appears to touch many pathways in cell culture may be acting at concentrations that are not physiologically achievable, or through nonspecific effects that will not translate to patients. Sorting genuine, dose-relevant mechanisms from laboratory artifacts is precisely what rigorous NCI preclinical work is designed to do.
Current Clinical Status and Expert Cautions
As of 2026, ivermectin is not FDA-approved for cancer and is not part of any standard oncology protocol. In fact, in May 2026 — a few months after the NCI news — ASCO issued a formal clinical notice recommending against the use of ivermectin (and fenbendazole) as cancer treatments outside of research settings. These two developments are not contradictory: the NCI is testing the hypothesis in the laboratory, while ASCO is cautioning patients against acting on an unproven hypothesis in the clinic.
The consistent expert message is that preclinical promise does not equal clinical efficacy. Patients understandably read an NCI investigation as validation, but the responsible interpretation is more measured: the science is being taken seriously enough to study properly, and the results — whatever they show — should guide any future use. Until then, self-medicating with ivermectin carries real risks, including drug interactions, neurological toxicity at high doses, and the possibility of delaying effective treatment. Anyone considering it should discuss it candidly with their oncologist rather than proceed alone.
Frequently Asked Questions
Does the NCI study mean ivermectin works against cancer?
No. The NCI began preclinical (laboratory and animal) studies in February 2026 to evaluate whether ivermectin has anticancer activity. This is an early research step. It signals the hypothesis is worth testing rigorously, not that efficacy in humans has been established.
Why is a government agency studying an off-patent drug?
Because ivermectin is off-patent, no company can profit from exclusive sales, so there is little commercial incentive to fund expensive trials. Public institutions like the NCI exist partly to investigate promising but commercially 'orphaned' hypotheses.
What is the difference between preclinical and clinical research?
Preclinical research uses cell cultures and animal models in the laboratory, before any human testing. Clinical research tests a drug in people through phased trials. Most drugs that succeed preclinically still fail in clinical trials, so preclinical results are an early checkpoint, not proof.
Is ivermectin FDA-approved for cancer?
No. Ivermectin is not FDA-approved for cancer and is not part of any standard oncology protocol. It is approved for certain parasitic infections. ASCO issued a clinical notice in May 2026 recommending against its use as a cancer treatment outside research.
Should I take ivermectin while the NCI studies it?
Medical experts advise against self-medicating. High doses carry neurological and interaction risks, and using an unproven drug can delay effective treatment. If you are interested, discuss it with your oncologist rather than starting on your own.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
6 / 12 / 18 mg — 100 tablets
180 capsules — 99% purity, laboratory tested
120 capsules — with Black Pepper for absorption
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- STAT News. "The National Cancer Institute is studying ivermectin as a cancer treatment." February 10, 2026. Link
- Oncology Nursing News. "National Cancer Institute Explores Ivermectin as a Potential Cancer Therapy." 2026. Link
- American Society of Clinical Oncology. "Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment." ASCO Connection, May 2026. Link
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.